haematologic condition who need staminal cells transplant
Conditions
Brief summary
Reducing the severity of GVHD
Detailed description
- Evaluation of circulating lymphocyte subpopulations on peripheral blood - Assessment of vitamin D receptor (VDR) surface expression and modulation in response to vitamin D treatment on lymphocyte subpopulations. - Evaluation of the soluble fraction of VDR on serum - post hoc evaluation of the role of polymorphisms (SNPs) of recipient and donor VDR on response to vitamin D therapy - collection of any adverse events brought about by cholecalciferol intake
Interventions
DRUGTREDIMIN 25.000 U.I. /2
DRUG5 ml soluzione orale
Sponsors
Azienda Ospedaliero Universitaria Pisana
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reducing the severity of GVHD | — |
Secondary
| Measure | Time frame |
|---|---|
| - Evaluation of circulating lymphocyte subpopulations on peripheral blood - Assessment of vitamin D receptor (VDR) surface expression and modulation in response to vitamin D treatment on lymphocyte subpopulations. - Evaluation of the soluble fraction of VDR on serum - post hoc evaluation of the role of polymorphisms (SNPs) of recipient and donor VDR on response to vitamin D therapy - collection of any adverse events brought about by cholecalciferol intake | — |
Countries
Italy
Outcome results
None listed